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PAPER
Anti-phospholipid-antibodies in patients with relapsing
polychondritis
M Zeuner1, RH Straub1, U Schlosser2, G Rauh3, G Schmitz2, J Scho¨lmerich1 and B Lang1
1University of Regensburg, Medical Center, Department of Internal Medicine I, Germany; 2University of Regensburg, Medical Center, Institute of Clinical
Chemistry and Laboratory Medicine, Germany; and 3Ludwig-Maximilian’s University Munich, Medical Policlinic, Germany
Relapsing polychondritis (RP) is an extremly rare multisystemic disease thought to be of
autoimmune origin. In order to assess if RP is associated with anti-phospholipid antibodies (aPL),
clinical data and sera of 21 patients with RP were collected in a multicentre study. Concentration of
anti-cardiolipin antibodies (aCL) (IgG-, IgM- and IgA-isotypes), anti-phosphatidylserine-antibodies
(aPS) (IgG- and IgM-isotypes) and anti-b-2-glycoprotein I-antibodies (ab2 GPI) were measured by
ELISA. In eight patients aCL were found to be elevated. One patient had elevated aPS. No patient
had elevated ab2 GPI. No patient had clinical signs and symptoms of a aPL syndrome.
Interestingly, the two RP patients with the highest aPL had concomitant systemic lupus
erythematosus (SLE). Therefore the presence of elevated aPL in RP is probably more closely
related to an associated SLE than to RP itself. There is no convincing evidence that aPL are
associated with RP.
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Introduction
Relapsing Polychondritis (RP) is a multisystemic
rheumatic disease, characterized by widespread and
potentially destructive inflammatory lesions of the
cartilage.1 The aetiology of RP is still unknown;
however, the high incidence of coexisting other
autoimmune or rheumatic diseases (such as SLE)
together with abundant anti-collagen autoantibodies
and with immunogenetic findings such as a HLA-DR4
association with susceptibility for RP2 provide
evidence that RP is an immunological disorder,
probably of autoimmune origin.
In many other autoimmune diseases, such as SLE,
aPL are prevalent.3 Like patients with primary aPL
syndrome these SLE patients have a higher frequency
of thrombosis, spontaneous abortion, thrombocytope-
nia, livedo reticularis and positive direct Coombs test
than SLE patients without aPL. In order to assess if
RP is like many other autoimmune diseases, also
associated with aPL, we measured aCL, aPS and ab2
GPI in 21 patients with RP and examined the patients
for clinical symptoms and signs of an aPL syndrome.
Patients and methods
Patients with RP were recruited in a multicentre study
between 1990 and 1995 from rheumatic disease units
in university hospitals and other tertiary referral
centers in Germany, Switzerland and the Netherlands.
From 21 of a total of 62 patients sera were available
for further analysis. All patients fulfilled the diag-
nostic criteria according to Mc Adam et al.4 and
Michet et al.5 Positive histology of the involved
cartilage was not required for inclusion, when clinical
diagnosis of RP was undoubted. To qualify for this
study a patient must have had proven inflammatory
episodes, involving at least two of three sites
(auricular, nasal and laryngotracheal cartilage) or
one of these sites together with two other manifesta-
tions, such as ocular inflammation, hearing loss,
vestibular dysfunction or seronegative inflammatory
arthritis.
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Clinical data were obtained by a questionnaire, sent
to the patient’s physician, requiring data about specific
disease manifestations, associated diseases, treatment
and follow up.
Serum concentration of aCL (IgG-, IgM- and
IgA-isotypes) (ELIAS, Freiburg, Germany), aPS
(IgG- and IgM-isotypes) (IMTEC, Zepernick, Ger-
many) and ab2 GPI (polyvalent) (IMTEC, Zepernick,
Germany) were measured using standardized com-
mercially available enzyme linked immunosorbent
assays (ELISA).6 The results are given in optical
densities (OD). Thirty healthy controls were used
for comparison (mean age 42.5 5.8 years). Cut
off values for positive results were defined as mean
plus 3 standard deviations (s.d.) of the results of
healthy controls. The cut off values were: aCL IgG:
0.449 OD, aCL IgM: 0.277 OD, aCL IgA: 0.237 OD,
aPS IgG: 0.943 OD, aPS IgM: 0.560 OD, ab2 GPI:
0.360 OD.
Statistical analysis was performed using the chi-
square test with Yates’ correction.
Clinical and immunogenetic findings of the 21
patients from this study have already been de-
scribed.2,7
Results
Demographic data
All 21 patients met the inclusion criteria for RP. Nine
patients were female and 12 male. The median age at the
time of diagnosis was 46.2 years with a range of 17–62
years.
Clinical data
Of the 21 patients, 18 had auricular chondritis, 13
ocular symptoms, 11 nasal chondritis, 10 laryngo-
tracheal involvement, eight arthritis, five vertigo,
five skin manifestations, four cardiovascular involve-
ment, three hearing loss, two central nervous
system involvement and one renal involvement. Some
of the patients’ clinical manifestations, e.g. cardiac,
may not necessarily be manifestations of the under-
lying RP, but be due to other concomitant conditions.
None of the patients showed signs of aPL syndrome
like recurrent fetal loss, thrombosis or livedo
reticularis. 2 patients suffered from migraine head-
ache, but they had no other signs of systemic
vasculitis. 6 of the 21 patients had an associated
disease (2 SLE, 4 rheumatoid arthritis). None of the
remaining 41 patients with RP, where no sera were
available for aPL testing, had signs of an aPL
syndrome.
Laboratory findings
Almost all patients showed non-specific increased
inflammatory activity in the laboratory tests. Erythro-
cyte sedimentation rate was elevated in 18 patients, C-
reactive protein in 10 patients. In 11 patients serum
protein electrophoresis showed signs of chronic
inflammation. In two patients mild (Coombs test
negative) anaemia and thrombocytopenia was de-
tected. No patient had prolonged activated partial
thromboplastin time or thrombocytopenia or positive
Coombs test. Rheumatoid factor was found in four
patients, three patients had anti-nuclear antibodies.
The two patients with associated SLE had positive
anti-nuclear antibodies with a homogenous pattern in
the indirect immunofluorescence staining, and had
anti-dsDNA antibodies.
The serum concentration of aCL (IgG-, IgM- and
IgA-isotypes), aPS (IgG- and IgM-isotypes) and ab2
GPI are shown in Figures 1 and 2. In eight patients
elevated aPL were detected. No patient had elevated
ab2 GPI. In patient no. 7, aCL IgG-isotype (0.463 OD)
and aPS IgG- (1.181 OD) were significantly elevated.
This patient suffered from associated SLE. The other
patient with SLE (no. 11) had also elevated aCL IgA-
(1.014 OD) and IgM-isotype (0.863 OD). Patients with
RP and associated SLE had significantly more often
aPL antibodies with compared patients with RP
without SLE (in 4 of 12 determinations vs in 7 of
114 determinations; P< 0.01). No other significant
association between clinical findings (e.g. thrombosis,
recurrent fetal loss, livedo reticularis, cerebral emboli)
and aPL could be found.
Discussion
RP is an extremely rare inflammatory disorder,
affecting cartilaginous structures throughout the
body.4,5,7 There is strong evidence suggesting im-
munologically mediated mechanisms in its pathogen-
esis. As in many other autoimmune diseases a high
prevalence of aPL can be found, we addressed the
question whether this is also the case in RP. Some
recent anecdotal cases suggested the possibility of an
association between aPL and RP. Balsa-Criado et al.8
reported one patient with lupus anticoagulant among
eight patients with RP. Quere et al.9 described two
patients with RP and positive lupus anticoagulant
suffering from vasculitis and thrombosis. In a recent
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study of a large series of RP patients, five were
identified to have an aPL syndrome.10 Four of these
five patients had other associated conditions (three of
them SLE, at least one had myelodysplasia). The
authors of this study concluded that aPL syndrome may
occur in RP, but is more closely related to associated
conditions like SLE.
The purpose of our study was, to evaluate the
prevalence of aPL and the aPL syndrome in an
unselected cohort of RP patients. In a recent study on
62 patients with RP we could not identify a single
patient with signs of a aPL syndrome.7 In the present
study on 21 patients with RP we found elevated aCL
in eight of them, aPS in one patient and ab2 GPI in no
patient. Interestingly the two patients with extremly
high aPL had associated SLE. Therefore, we speculate
that aPL elevation in these two patients is more likely
to be associated with the underlying SLE than with
RP. None of the eight patients with elevated aPL had
signs of an aPL syndrome.
In conclusion, there is no convincing evidence that RP
itself is associated with aPL. If aPL occurs in RP it seems
to be more closely related to associated conditions like
SLE. Therefore patients with RP and clearly elevated
aPL serum concentrations should be carefully investi-
gated for other autoimmune diseases such as SLE.
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Figure 1 Concentration of anti-cardiolipin antibodies (aCL) in 21
patients with relapsing polychondritis (cut off values for positive results:
aCL IgG: 0.449 OD, aCL IgM: 0.277 OD, aCL IgA: 0.237 OD).
Figure 2 Concentration of anti-phosphatidylserine antibodies (aPS) in 21
patients with relapsing polychondritis (cut off values for positive results:
aPS IgG: 0.943 OD, aPS IgM: 0.560 OD).
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